- Home
- SOR vs XOMA Comparison
SOR vs XOMA Comparison
Compare SOR & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOR | XOMA |
|---|---|---|
| Founded | N/A | 1981 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.6M | 471.6M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | SOR | XOMA |
|---|---|---|
| Price | $45.22 | $41.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $52.50 |
| AVG Volume (30 Days) | 13.8K | ★ 363.8K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $29.64 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.93 | $22.29 |
| 52 Week High | $50.41 | $42.81 |
Technical Indicators
Market Signals| Indicator | SOR | XOMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.01 | 63.65 |
| Support Level | $44.03 | $37.00 |
| Resistance Level | $46.92 | $42.15 |
| Average True Range (ATR) | 0.60 | 0.43 |
| MACD | -0.12 | -0.35 |
| Stochastic Oscillator | 18.51 | 46.80 |
Price Performance
Historical ComparisonAbout SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates. The Company's drug royalty aggregator business is mainly focused on the acquisition of early to mid-stage clinical assets. Geographically, the company operates in Switzerland, the United States, Asia Pacific, Europe, and other regions.